Genmab A/S (GMABN.MX)
Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
At close: 01:16PM CST
| Previous Close | 4,837.35 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 5,100.00 - 5,100.00 |
| 52 Week Range | 4,907.84 - 5,375.45 |
| Volume | |
| Avg. Volume | 1,512 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | 45.57 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investor's Business Daily
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.
- Reuters
Denmark's Genmab to acquire ProfoundBio for $1.8 billion
The acquisition will give Genmab worldwide rights to three candidates in clinical development, they said. Genmab shares were down 1.7% at 0955 GMT. Jyske bank analyst Henrik Hallengreen Laustsen said that while the acquisition is seen as slightly positive for Genmab shares, the price is difficult to assess, and added it might be "a bit high".
- Zacks
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
© 2024 Yahoo. All rights reserved.